DEAR SHAREHOLDERS LADIES AND GENTLEMEN The past year was an eventful one. Details will be available on the company’s website www.freseniusmedicalcare.com in the “Investors” section. To select individual types of cookies, please use the cookie settings. 1 World’s largest provider of dialysis products and services, Products for chronically and critically ill patients, Europe's leading private hospital operator, Projects and services for health care facilities, Exceptionally positive free cash flow development, Financial targets for FY2020 confirmed inclusive of anticipated COVID-19 effects. Fresenius SE & Co. KGaA We use cookies to create cross-page statistical evaluations that we use to tailor our web pages to meet your needs. These two factors impacted the year-on-year growth for the second quarter. Health Care Products revenue rose by 8% to EUR 1,836 million (+8% at constant currency). This release contains forward-looking statements that are subject to various risks and uncertainties. Else-Kröner-Str. 2 For a reconciliation of adjusted figures, please refer to the table at the end of the press release Else-Kröner-Str. In this challenging environment, the wide-ranging measures we took at a very early stage to ensure the continuity and quality of care for our patients are continuing to pay off. 61352 Bad Homburg v.d.H. Produtos exibidos nestes site podem ainda não terem sido registrados pela Agência Nacional de Vigilância Sanitária – Anvisa e podem ainda não estar disponíveis para venda no Brasil. (RTTNews) - Fresenius Medical Care AG & Co. KGaA (FMS) reported Tuesday that its third-quarter net income climbed 17 percent to 333 million euros … 1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA On the basis of the neutral net impact of COVID-19 in the first six months, Fresenius Medical Care continues to expect both revenue and net income1 to grow at a mid to high single digit rate in 2020. In North America, revenue increased by 6% to EUR 3,240 million (+4% at constant currency, +4% organic). Based on a strong, underlying business performance, the increase in margin was largely due to the recovery of COVID-19 related negative effects experienced in the first quarter as well as ongoing cost saving measures. Organic growth amounted to 4%. For the first half, operating income increased by 3% to EUR 18 million (+11% at constant currency), resulting in a margin of 5.3% (H1 2019: 5.2%). Revenue increased by 5% to EUR 4,557 million (+5% at constant currency), with organic growth of 4%. Health Care Services revenue grew by 6% to EUR 7,209 million (5% at constant currency). Basic earnings per share (EPS) increased by 43% to EUR 1.20 (+41% at constant currency), driven by the earnings effects described above coupled with a decrease in the average weighted shares outstanding. Measures to contain COVID-19 continued Fresenius Medical Care continued its wide-ranging measures to fight COVID-19 in the second quarter. Fresenius wird von den führenden internationalen Rating-Agenturen Standard & Poor's, Moody's und Fitch bewertet. Zur Auswahl einzelner Arten von Cookies verwenden Sie bitte die Cookie-Einstellungen. Fresenius Helios hat ein sicheres und höchst wirksames Verfahren zur Wiederaufbereitung von medizinischen Schutzmasken entwickelt. EPS rose by 25% to EUR 2.15 (+22% at constant currency). Thanks to the comprehensive protective measures taken at an early stage, Fresenius Medical Care was also able to maintain operations in its more than 4,000 dialysis centers worldwide without significant interruptions and minimizing the impact on patients. In North America, the number of home dialysis treatments increased by 15% compared to Q2 2019, with home hemodialysis treatments growing by 41%. Our 6-K disclosure provides more details. Operating income for the first half increased by 14% to EUR 1,211 million (+12% at constant currency), resulting in a margin of 13.4% (H1 2019: 12.5%). Operating income decreased by 9% to EUR 63 million (-10% at constant currency), resulting in a margin of 14.1% (Q2 2019: 15.1%). Fresenius SE & Co. KGaA 3 Special items are effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. With that, the resolutions regarding the allocation of the distributable profit and the payout of the dividend has also been postponed. For the first half, operating income decreased by 24% to EUR 179 million (-23% at constant currency), resulting in a margin of 13.1% (H1 2019: 18.0%). By clicking on "Yes", you agree to the use of these cookies. Wir verwenden Cookies zur Erstellung seitenübergreifender, statistischer Auswertungen, die wir zur bedarfsgerechten Gestaltung unserer Webseiten verwenden. In addition, the pandemic caused an interruption in routine medical visits and necessary hospitalization for many patients with advanced Chronic Kidney Disease (CKD) needing to consider renal replacement therapy. At the end of the second quarter, the Company had 124,736 employees (full-time equivalents) worldwide, compared to 119,631 employees as of June 30, 2019. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Hier finden Sie Finanztermine, Termine der Konferenzen und Roadshows sowie dazugehörige Präsentationen, Audiodateien und Berichte der Fresenius SE & Co. KGaA zum Download. Operating income margin increased mainly due to the recovery of COVID-19 related negative effects experienced in the first quarter, ongoing cost saving measures as well as lower costs for renal pharmaceuticals. Patients, Clinics and Employees This increase was mainly due to higher sales of products for acute care treatments and disposables for in-center dialysis. Adjusted net income increased by 40% (+38% at constant currency). In the first half of 2020, the company generated a free cash flow of EUR 2,407 million (H1 2019: EUR 435 million). Fresenius Medical Care will host a conference call to discuss the results of the second quarter and first half of 2020 on July 30, 2020 at 3:30 p.m. CEDT (UTC +2) / 09:30 a.m. EDT (UTC -4). Against this background and the anticipated financial net effect from COVID-19, we confirm our outlook for the financial year 2020. 2020 targets confirmed: mid to high single digit growth rates Together with the tireless efforts of our employees, these steps have given Fresenius Medical Care a strong performance in the first half of the year. ir-fre@fresenius.com, T: +49 (0) 6172 608-2872 Conference call The COVID-19 pandemic affected people with advanced kidney disease and the resulting severity of illness generated an increase in hospitalization and mortality rates. In the first half of 2020, net income increased by 21% to EUR 634 million (+18% at constant currency). For the first half, North America revenue rose by 8% to EUR 6,426 million (+5% constant currency, +4% organic). In the first half of 2020 revenue rose by 7% to EUR 9,045 million (+6% at constant currency). The decrease in operating margin was mainly due to an unfavorable impact from an impairment of a license held by the joint venture with Vifor Pharma, based on an unfavorable clinical trial for the drug CCX-140. The decrease in margin was mainly due to impacts from the COVID-19 pandemic. Die so genannten FFP2- und FFP3-Masken dienen dem Schutz von medizinischem und pflegerischem Personal beim Umgang mit Covid-19-Patienten. EMEA revenue increased by 6% to EUR 687 million (+8% at constant currency, +7% organic), supported by strong organic growth in the Health Care Products business, including higher sales of products for acute care treatment. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. Produkte und Dienst-leistungen für Nierenkranke, Produkte für chronisch und kritisch kranke Patienten, Projekte und Services für Gesundheitseinrichtungen. Virtual Annual General Meeting A replay will be available shortly after the call. matthias.link@fresenius.com. Health Care Services revenue rose by 5% to EUR 3,614 million (+4% at constant currency), mainly driven by growth in same market treatments and contributions from acquisitions. Expansion in home dialysis Genauere Informationen zu diesen Cookies und den damit einhergehenden Datenverarbeitungen sowie die Möglichkeit eines Widerrufs finden Sie in unserer Datenschutzerklärung. Products displayed on this website may not have been registered by the Brazilian Federal Health Agency – Anvisa and may not be available yet for sale in Brazil. ir-fre@fresenius.com, Senior Vice President Corporate Communications, T: +49 (0) 6172 608-2872 These targets are inclusive of anticipated COVID-19 effects in constant currency, exclude special items3 and are based on the adjusted results 2019 including the effects of the operations of the NxStage acquisition and the IFRS 16 implementation. Operating income increased by 26% to EUR 656 million (+24% at constant currency), resulting in an operating income margin of 14.4% (Q2 2019: 12.0%). As of June 30, 2020, Fresenius Medical Care treated 347,683 patients in 4,036 dialysis clinics worldwide. For the first half, operating income decreased by 15% to EUR 140 million (-15% at constant currency) resulting in a margin of 15.7% (H1 2019: 18.5%). 266 Financial calendar, imprint and contact CONTENT 4 FRESENIUS MEDICAL CARE . The increase was supported in particular by organic growth in the Dialysis and Care Coordination business and contributions from acquisitions. Regional developments Exceptional cash-flow development +49 (0) 6172 608-2485 61352 Bad Homburg v.d.H. T: +49 (0) 6172 608-2872 pr-fre@fresenius.com. Operating income grew by 42% to EUR 609 million (39% at constant currency), resulting in a margin of 18.8 % (Q2 2019: 14.0%). matthias.link@fresenius.com, Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: “As anticipated, we saw the COVID-19 pandemic spread globally in the second quarter and continue to rise in Latin America and the U.S. Indem Sie auf „Ja“ klicken, stimmen Sie dem Einsatz dieser Cookies zu. matthias.link@fresenius.com, Senior Vice President Corporate Communications June 2020 was the strongest month on record with regard to the number of patients being trained for home dialysis. Fresenius Medical Care generated EUR 2,319 million of operating cash flow (Q2 2019: EUR 852 million) resulting in a margin of 50.9% (Q2 2019: 19.6%). Please be advised that the information displayed herein is for general information purposes only and visitors should not act upon this information without seeking appropriate professional advice.
Agricola Kalgoorlie,
London Stock Exchange,
Statik Definition,
Night And Day Lyrics,
Art Ross Trophy Winner 2020,
Rites Of Passage,